|
|
| | Repertaxin Basic information |
| Product Name: | Repertaxin | | Synonyms: | Reparixin;Repertaxin;DF 1681Y;(R)-(-)-N-2-[(4-Isobutylphenyl)propionyl]methanesulfonamide;Repertaxin(R-configuration, free base form);REPARIXIN;DF 1681Y;DF 1681Y;REPERTAXIN;Reparixin (Repertaxin | | CAS: | 266359-83-5 | | MF: | C14H21NO3S | | MW: | 283.39 | | EINECS: | | | Product Categories: | | | Mol File: | 266359-83-5.mol |  |
| | Repertaxin Chemical Properties |
| Melting point | 103-105℃ | | density | 1.137±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | Soluble in DMSO (up to 100 mg/ml) or in Ethanol (up to 25 mg/ml) | | pka | 4.28±0.40(Predicted) | | form | solid | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| | Repertaxin Usage And Synthesis |
| Description | Reparixin (CAS 266359-83-5) is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors (IC50?= 1 and 100 nM, respectively). It blocks a number of activities related to IL-8 signaling, including leukocyte recruitment (IC50?= 1 nM) without affecting receptor activation induced by other CXCR1 and CXCR2 agonists.1?In spontaneously hypertensive rats, 5 mg/kg reparixin administered daily for three weeks was shown to reduce blood pressure by inhibiting hypertension-related mediators.2?It attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.3?Reparixin blockade (100 nM) of CXCR1 has also been used to deplete a cancer stem cell population in human breast cancer cell lines?in vitro.4 | | Uses | Prevention of delayed graft function in solid organ transplant (CXCL8 inhibitor). | | Uses | Reparixin is an inhibitor of CXCR1 and CXCR2 chemokine receptors. Functions as an agent that blocks a range of activities including leukocyte recruitment and IL-8 signaling. | | Definition | ChEBI: Reparixin is a monoterpenoid. | | References | 1) Bertini?et al.?(2004),?Non-competitive allosteric inhibitors of the inflammatory cytokine receptors CXCR1 and CXCR2: prevention of reperfusion injury; Proc. Natl. Acad. Sci. USA,?101?11791
2) Kim?et al. (2011),?Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats; Biol. Pharm. Bull.,?34?120
3) Gorio?et al.?(2007),?Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord; J. Pharmacol. Exp. Ther.,?322?973
4) Ginestier?et al.?(2010),?CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts; J. Clin. Invest.,?120?485 |
| | Repertaxin Preparation Products And Raw materials |
|